1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
试验速览
- 阶段
- 不适用
- 入组人数
- 93
- 主要终点
- Comparison of vital status
研究概览
简要总结
This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX).
Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology.
The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called "Method and Teaching of Scientific Studies".
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18,
- •No Trimethylxanthine contraindications (defined as allergy, previous reported secondary effects),
- •Infectious Disease Unit admission.
排除标准
- •Secondary effects about Trimethylxanthine,
- •Refuse to participate
结局指标
主要结局
Comparison of vital status
时间窗: 6 days
the patient clinical status at day 6 after hospital admission, defined as alive, or dead.
次要结局
- Comparaison of duration of hospital stay(6 days)
- Comparaison of severity(6 days)
- Comparaison of secondary effects (adverse events that needed disruption of treatment (anemia, tachycardia, osteoporosis) : secondary effects of coffee).(6 days)
- Comparaison of use of antibiotics(14 days after hospital admission.)